TrialHuman vaccines & immunotherapeutics2021

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.

Prakash K Bhuyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.